AT7519 Induces Eosinophil Apoptosis and Resolves Allergic Inflammation
Author Information
Author(s): Alessandri Ana L., Duffin Rodger, Leitch Andrew E., Lucas Christopher D., Sheldrake Tara A., Dorward David A., Hirani Nik, Pinho Vanessa, de Sousa Lirlândia Pires, Teixeira Mauro M., Lyons John F., Haslett Christopher, Rossi Adriano G.
Primary Institution: Medical Research Council Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, Scotland, United Kingdom
Hypothesis
Can the cyclin-dependent kinase inhibitor AT7519 enhance the resolution of eosinophilic inflammation by inducing eosinophil apoptosis?
Conclusion
AT7519 effectively induces eosinophil apoptosis and promotes the resolution of allergic pleurisy in a murine model.
Supporting Evidence
- AT7519 induced eosinophil apoptosis in a concentration-dependent manner.
- Therapeutic administration of AT7519 enhanced the resolution of allergic pleurisy.
- The effects of AT7519 were reduced by a caspase inhibitor, indicating a caspase-dependent mechanism.
Takeaway
A new drug called AT7519 helps the body get rid of bad cells that cause allergies by making them die off faster.
Methodology
Eosinophils were treated with AT7519 and assessed for apoptosis using flow cytometry and a murine model of allergic pleurisy was used to evaluate the drug's effects in vivo.
Limitations
The study primarily focused on a murine model, which may not fully replicate human responses.
Participant Demographics
Healthy adult donors provided eosinophils for the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website